This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jose S. Pulido, MD; Kim S. Mallick, MD; Scott R. Sneed, MD; Christopher F. Blodi, MD
Iowa City

Arch Ophthalmol. 1989;107(3):316-317.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Topical 1% apraclonidine hydrochloride, an -adrenergic agonist, reduces intraocular pressure in normal volunteers by approximately 40%.¹ The onset of action occurs within one hour and the maximum intraocular pressure reduction usually appears three to five hours after application of a single dose. Its efficacy in decreasing acute intraocular pressure elevation following anterior segment laser surgery has been demonstrated.² Apraclonidine has not been approved by the Food and Drug Administration for use after retinal reattachment or vitreous surgery. We report the use of apraclonidine in two patients to reduce the intraocular pressure elevation following pneumatic retinopexy and nondrainage retinal reattachment surgery.

Report of Cases.

—PATIENT 1. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?